Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
desflurane + remifentanil (Bakırköy Dr. Sadi Konuk Research and Training Hospital)
- Development stage
- Phase 4
- Lead developer
- Bakırköy Dr. Sadi Konuk Research and Training Hospital
- Modality
- Small Molecules
- Administration
- Inhalation, Intravenous
01
Overview
Desflurane + remifentanil is a combination anesthetic regimen utilized for the maintenance of general anesthesia. Desflurane is a volatile, inhalational methyl ethyl ether anesthetic that acts as a positive allosteric modulator of GABA-A and glycine receptors and an antagonist of NMDA receptors, primarily providing hypnosis and muscle relaxation. Remifentanil is a potent, ultra-short-acting synthetic mu-opioid receptor agonist that provides intense intraoperative analgesia. This specific combination is frequently used in clinical research, such as the trial conducted by Bakirkoy Dr. Sadi Konuk Research and Training Hospital, as a standard-of-care comparator for evaluating alternative maintenance strategies like dexmedetomidine. The regimen is characterized by rapid onset and offset of action, allowing for precise control of anesthetic depth and fast postoperative recovery.
- Other names
- desflurane and remifentanil
02
Targets
GABRR (GABA-A receptor subunit rho)Glycine receptorMOR (Mu opioid receptor)GABRA2 (Gamma-aminobutyric acid receptor subunit alpha 2)NMDAR (Glutamate receptor ionotropic, NMDA)
Beyond the preview
Go deeper on desflurane + remifentanil (Bakırköy Dr. Sadi Konuk Research and Training Hospital).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on desflurane + remifentanil (Bakırköy Dr. Sadi Konuk Research and Training Hospital).